

Ref: MHL/Sec&Legal/2023-24/39

Date: August 02, 2023

To,
Head, Listing Compliance Department
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001.

To,
Head, Listing Compliance Department,
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1. G Block,
Bandra – Kurla Complex, Bandra (East),
Mumbai – 400 051

Scrip Code: 542650

Scrip Symbol: METROPOLIS

Sub: Outcome of Board Meeting held on Wednesday, August 02, 2023

Ref: Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('LODR')

Dear Sir/ Madam,

This is to inform you that the Board of Directors of the Company at their Meeting held today i.e. Wednesday, August 02, 2023, have inter- alia considered and approved:

- Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2023 and took note of the Limited Review Report issued by the Statutory Auditors of the Company.

The copy of Unaudited Standalone & Consolidated Financial Results of the Company as approved by the Board of Directors together with the Limited Review Report thereon for the quarter ended June 30, 2023 are enclosed as Annexure-1

- Appointment of Mr. Subramanian Ranganathan (DIN: 00125493) as an Additional Director in the category of Non-Executive Independent Director of the Company for a term of 5 years with effect from August 21, 2023, subject to approval of shareholders.

Further, we would like to state that as per the requirement of Circular No. LIST/COMP/74/2018-19 dated June 20, 2018 w.r.t. Enforcement of SEBI orders regarding appointment of directors by listed companies, we hereby affirm that Mr. Subramanian Ranganathan, is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.

Details pursuant to SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015 are enclosed herewith as "Annexure-2"

- Reconstitution of Board Committees of the Company with effect from effect from September 07, 2023, details are enclosed herewith as "Annexure-3"
- Appointment of Mr. Mohan Menon as Chief Marketing Officer, Senior Management Personnel of the Company, details are enclosed herewith as "Annexure-4"

METROPOLIS
The Pathology Specialist

BLOOD TESTS • DIAGNOSTICS • WELLNESS

Metropolis Healthcare Limited

Registered & Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030.
CIN: L73100MH2000PLC192798 Te. No.: 8422 801 801 Email: support@metropolisindia.com
Website: www.metropolisindia.com
Global Reference Laboratory: 4th Floor, Commercial Building-1A, Kohnoor Mall, Vidyavihar (W), Mumbai - 400 070.

The meeting commenced at 02:15 p.m. (IST) and concluded at 05:40 p.m. (IST)

You are requested to kindly take the same on record.

Thanking you,

Yours faithfully

For Metropolis Healthcare Limited



Neha Shah
Interim Company Secretary & Compliance Officer
Membership No. A51465

Encl. a/a

BLOOD TESTS • DIAGNOSTICS • WELLNESS

METROPOLIS
The Pathology Specialist

Metropolis Healthcare Limited

Registered & Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030.

CIN: L73100MH2000PLC192798 Tel No.: 8422 801 801 Email: support@metropolisindia.com

Website: www.metropolisindia.com

Global Reference Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070.

BSR & Co. LLP

Chartered Accountants

14th Floor, Central B Wing and North C Wing,
Nesco IT Park 4, Nesco Center,
Western Express Highway,
Goregaon (East), Mumbai – 400063, India
Telephone: +91 (22) 6257 1000
Fax: +91 (22) 6257 1010

Limited Review Report on unaudited standalone financial results of Metropolis Healthcare Limited for the quarter ended 30 June 2023 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Metropolis Healthcare Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Metropolis Healthcare Limited (hereinafter referred to as "the Company") for the quarter ended 30 June 2023 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the three months ended 31 March 2023 as reported in the Statement, are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **BSR & Co. LLP**

Chartered Accountants

Firm's Registration No.: 101248W/W-100022



Rajesh Mehra

Partner

Mumbai

02 August 2023

Membership No.: 103145

UDIN: 23103145BGXWXO5600

Metropolis Healthcare Limited

Registered and Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400030

CIN:L73100MH2000PLC192798

Tel. No.: 022 6258 2810

Email: support@metropolisindia.com

Website: www.metropolisindia.com

Global Reference Lab: 4th Floor Commercial Bldg. - 1A, Kohinoor Mall, Vidyavihar (West), Mumbai - 400070



Statement of Standalone Financial Results for the quarter ended 30 June 2023

(Rs. in Lakhs)

Sr. No.	Particulars	Quarter ended			Year ended
		30 June 2023 (Unaudited)	31 March 2023 (Audited)	30 June 2022 (Unaudited)	31 March 2023 (Audited)
1	Income				
	a) Revenue from operations	25,629.34	26,440.55	25,702.05	106,604.07
	b) Other income	278.13	913.85	242.41	2,128.26
	Total Income	25,907.47	27,354.40	25,944.46	108,732.33
2	Expenses				
	a) Cost of material consumed	5,279.38	5,355.35	5,729.41	23,554.58
	b) Laboratory testing charges	234.74	135.47	217.20	574.87
	c) Employee benefits expense	5,847.19	5,706.14	5,722.91	22,816.29
	d) Finance costs	582.51	630.42	750.23	2,669.18
	e) Depreciation and amortisation expense	1,998.64	2,223.16	2,037.28	8,495.60
	f) Other expenses	8,441.79	8,471.69	7,929.84	32,727.29
	Total Expenses	22,384.25	22,522.23	22,386.87	90,837.81
3	Profit before tax (1) - (2)	3,523.22	4,832.17	3,557.59	17,894.52
4	Tax expenses				
	Current tax	947.20	1,051.26	941.76	4,500.05
	Deferred tax expense/(income)	(37.31)	5.56	(176.94)	(241.78)
	Tax adjustments for earlier years	-	(217.53)	(44.78)	(258.48)
	Total tax expenses	909.89	839.29	720.04	3,999.79
5	Profit for the period/year (3) - (4)	2,613.33	3,992.88	2,837.55	13,894.73
6	Other comprehensive income				
	Items that will not be reclassified subsequently to profit and loss (net of tax)	(40.93)	(27.36)	(20.38)	(163.72)
	Items that will be subsequently reclassified to profit and loss (net of tax)	-	-	-	-
	Other comprehensive income for the period /year (net of tax)	(40.93)	(27.36)	(20.38)	(163.72)
7	Total comprehensive income (5) + (6)	2,572.40	3,965.52	2,817.17	13,731.01
8	Paid-up equity share capital (face value - Rs. 2 per share)	1,024.22	1,024.21	1,023.48	1,024.21
9	Other equity	-	-	-	92,577.43
10	Earnings per share (Face value of Rs. 2 each) basic- (Rs.)*	5.10	7.80	5.54	27.14
	Earnings per share (Face value of Rs. 2 each) diluted - (Rs.)*	5.09	7.78	5.52	27.05

(*not annualised for the quarters)

See accompanying notes to the unaudited standalone financial results



NOTES:

- 1 The standalone financial results have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India.
- 2 The standalone financial results of the Company have been reviewed by the Audit Committee at their meeting held on 02 August 2023 and thereafter approved by the Board of Directors at their meeting held on 02 August 2023. The statutory auditors have issued an unmodified review report on the above standalone financial results.
- 3 The figures for the three months ended 31 March 2023 are arrived at as difference between audited figures in respect of the full financial year and unaudited published figures up to nine months ended 31 December 2022.
- 4 Disclosure of segment –wise information is not applicable, as pathology services is the Company's only business segment.
- 5 The Board of Directors of the Company, at their meeting held on 11 February 2022, accorded in-principle approval for the voluntary liquidation of Dr. Ganesan's Hitech Diagnostic Centre Private Limited ('Hitech'), a wholly owned subsidiary of the Company, to be carried out under the provisions of Insolvency and Bankruptcy Code, 2016. The Board of Directors of Hitech in their meeting dated 01 April 2022 and the members of Hitech in their Extra Ordinary General meeting held on 01 April 2022 have accorded their approval for consolidation of the business of Hitech through voluntary liquidation process. Pursuant to the ongoing liquidation process, the liquidator of Hitech has transferred the entire business undertaking to the Company on a going concern basis on and with effect from 04 June 2022.
- 6 On 16 November 2022, the Income Tax department conducted searches at the premises of the Company and some of its subsidiaries. No assets of the Company or its subsidiaries were seized during this process. The Company has been providing from time to time the information and clarifications sought by the Income Tax authorities. Subsequently, including during the current quarter, the Company and some of its subsidiaries have received notices under sections 147 and 148 of the Income Tax Act, 1961, that provide for the reopening of past assessment proceedings. Presently, there is no demand, and accordingly, no adjustments have been made in the financial results.
- 7 On review of the pattern of consumption of the future economic benefits embodied in the assets, it was noted that there has been change in expected pattern of consumption of these benefits. Accordingly, with effect from 01 April 2023, the Company has changed its depreciation/amortization method to Straight Line method from Written down value method for various class of assets to reflect this change. Such a change has been accounted for as a change in an accounting estimate in accordance with Ind AS 8 "Accounting Policies, Change in Accounting Estimates and Errors". Had the Company continued the previous Written Down Value Method for charging depreciation on all class of assets, charge for depreciation/amortisation for the quarter ended 30 June 2023 and for future period would have been higher by Rs. 265.38 lakhs and Rs. 662.36 lakhs respectively and consequentially deferred tax charge on the same for the quarter ended 30 June 2023 and for future period would have been lower by Rs. 66.80 lakhs and Rs. 166.72 lakhs respectively.
- 8 The standalone financial results of the Company are available for investors at www.metropolisindia.com, www.nseindia.com and www.bseindia.com.

Metropolis Healthcare Limited


Ameera Shah
Managing Director
DIN: 00208095
Place: Mumbai
Date: 02 August 2023



B S R & Co. LLP

Chartered Accountants

14th Floor, Central B Wing and North C Wing,
Nesco IT Park 4, Nesco Center,
Western Express Highway,
Goregaon (East), Mumbai – 400063, India
Telephone: +91 (22) 6257 1000
Fax: +91 (22) 6257 1010

Limited Review Report on unaudited consolidated financial results of Metropolis Healthcare Limited for the quarter ended 30 June 2023 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Metropolis Healthcare Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Metropolis Healthcare Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30 June 2023 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.
4. The Statement includes the results of the entities mentioned in Annexure I to the Statement.
5. Attention is drawn to the fact that the figures for the three months ended 31 March 2023 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review report of the other auditor referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Registered Office:

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063

B S R & Co. (a partnership firm with Registration No. BA61223) converted into B S R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013

Limited Review Report (Continued)

Metropolis Healthcare Limited

7. We did not review the interim financial information of one (1) subsidiary included in the Statement, whose interim financial information reflects total revenues (before consolidation adjustments) of Rs 323.80 lakhs, total net profit after tax (before consolidation adjustments) and total comprehensive income (before consolidation adjustments) of Rs. 48.97 lakhs, for the quarter ended 30 June 2023, as considered in the Statement. This interim financial information has been reviewed by other auditor whose report has been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter.

8. The Statement includes the interim financial information of 7 (seven) subsidiaries which have not been reviewed, whose interim financial information reflects total revenues (before consolidation adjustments) of Rs. 1,968.43 lakhs, total net profit after tax (before consolidation adjustments) of Rs. 222.39 lakhs and total comprehensive income (before consolidation adjustments) of Rs. 33.90 lakhs, for the quarter ended 30 June 2023, as considered in the Statement. According to the information and explanations given to us by the Parent's management, these interim financial information are not material to the Group.

Our conclusion is not modified in respect of this matter.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.: 101248W/W-100022



Rajesh Mehra

Partner

Mumbai

02 August 2023

Membership No.: 103145

UDIN: 23103145BGXWXP5356

Limited Review Report (Continued)

Metropolis Healthcare Limited

Annexure I

List of entities included in unaudited consolidated financial results.

Sr. No	Name of component	Relationship
1	Metropolis Healthcare Limited	Parent
1	Ekopath Metropolis Lab Services Private Limited	Subsidiary
2	Amins Pathology Laboratory Private Limited	Wholly owned subsidiary
3	Metropolis Histoexpert Digital Services Private Limited	Wholly owned subsidiary
4	Centralab Healthcare Services Private Limited	Wholly owned subsidiary
5	Metropolis Healthcare (Mauritius) Limited	Wholly owned subsidiary
6	Metropolis Star Lab Kenya Limited	Wholly owned subsidiary
7	Metropolis Healthcare Ghana Limited	Wholly owned subsidiary
8	Metropolis Bramser Lab Services (Mtius) Limited	Wholly owned subsidiary
9	Metropolis Healthcare (Tanzania) Limited	Wholly owned subsidiary
10	Metropolis Healthcare Lanka Private Limited	Wholly owned subsidiary
11	Metropolis Healthcare Uganda Limited	Wholly owned subsidiary





Metropolis Healthcare Limited

Registered and Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400030

CIN L73100MH2000PLC192798

Tel. No.: 022 6258 2810

Email: support@metropolisindia.com

Website: www.metropolisindia.com

Global Reference Lab: 4th Floor Commercial Bldg. - 1A, Kohinoor Mall, Vidyavihar (West), Mumbai - 400070

Statement of Consolidated Financial Results for the quarter ended 30 June 2023

(Rs. in Lakhs)

Sr. No.	Particulars	Quarter ended			Year ended
		30 June 2023 (Unaudited)	31 March 2023 (Audited)	30 June 2022 (Unaudited)	31 March 2023 (Audited)
1	Income				
	a) Revenue from operations	27,709.11	28,254.60	27,985.86	1,14,821.02
	b) Other income	305.25	122.63	303.89	1,522.46
	Total Income	28,014.36	28,377.23	28,289.75	1,16,343.48
2	Expenses				
	a) Cost of material consumed	5,695.94	5,950.71	6,145.37	25,326.40
	b) Laboratory testing charges	242.04	33.56	273.97	657.09
	c) Employee benefits expense	6,505.83	6,431.47	6,221.11	25,273.41
	d) Finance costs	598.06	617.45	752.85	2,680.15
	e) Depreciation and amortisation expense	2,082.05	2,343.46	2,117.32	8,921.56
	f) Other expenses	8,971.44	8,810.24	8,496.26	34,734.53
	Total Expenses	24,095.36	24,186.89	24,006.88	97,593.14
3	Profit before tax (1) - (2)	3,919.00	4,190.34	4,282.87	18,750.34
4	Tax expenses				
	Current tax	1,107.95	1,143.75	1,160.82	5,127.43
	Deferred tax expense/(income)	(109.24)	(84.78)	(189.66)	(458.09)
	Tax adjustments for earlier years	22.24	(217.53)	(44.70)	(258.40)
	Total tax expenses	1,020.95	841.44	926.46	4,410.94
5	Profit for the period / year (3) - (4)	2,898.05	3,348.90	3,356.41	14,339.40
6	Other comprehensive income				
	Items that will not be reclassified subsequently to profit and loss (net of tax)	(40.93)	(27.52)	(20.38)	(164.58)
	Items that will be subsequently reclassified to profit and loss (net of tax)	(188.49)	(68.78)	18.13	129.74
	Other comprehensive income for the period /year (net of tax)	(229.42)	(96.30)	(2.25)	(34.84)
7	Total comprehensive income (5) + (6)	2,668.63	3,252.60	3,354.16	14,304.56
8	Profit attributable to:				
	Owners of the Company	2,879.60	3,335.52	3,339.74	14,288.26
	Non-controlling interest	18.45	13.38	16.67	51.14
9	Other comprehensive income attributable to:				
	Owners of the Company	(229.62)	(96.44)	(2.25)	(34.70)
	Non-controlling interest	0.20	0.14	-	(0.14)
10	Total comprehensive income attributable to:				
	Owners of the Company	2,649.98	3,239.09	3,337.49	14,253.56
	Non-controlling interest	18.65	13.51	16.67	51.00
11	Paid-up equity share capital (face value - Rs. 2 per share)	1,024.21	1,024.21	1,023.48	1,024.21
12	Other equity (including Non-controlling interest)				97,799.02
13	Earnings per share (Face value of Rs 2each) basic- (Rs.)*	5.62	6.51	6.53	27.91
	Earnings per share (Face value of Rs 2 each) diluted - (Rs.)*	5.61	6.49	6.49	27.81

(*not annualised for the quarters)

See accompanying note to the unaudited consolidated financial results



NOTES:

- 1 Metropolis Healthcare Limited (the 'Company' or the 'Parent') and its subsidiaries (referred collectively as the 'Group') are primarily involved in providing pathology and related healthcare services.
- 2 The consolidated financial results have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India.
- 3 The consolidated financial results of the Company have been reviewed by the Audit Committee at their meeting held on 02 August 2023 and thereafter approved by the Board of Directors at their meeting held on 02 August 2023. The statutory auditors have issued unmodified review report on the above consolidated financial results.
- 4 The figures for the three months ended 31 March 2023 are arrived at as difference between audited figures in respect of the full financial year and unaudited published figures up to nine months ended 31 December 2022.
- 5 Disclosure of segment-wise information is not applicable, as pathology services is the Group's only business segment.
- 6 The Board of Directors of the Company, at their meeting held on 11 February 2022, accorded in-principle approval for the voluntary liquidation of Dr. Ganesan's Hitech Diagnostic Centre Private Limited ('Hitech'), a wholly owned subsidiary of the Company, to be carried out under the provisions of Insolvency and Bankruptcy Code, 2016. The Board of Directors of Hitech in their meeting dated 01 April 2022 and the members of Hitech in their Extra Ordinary General meeting held on 01 April 2022 have accorded their approval for consolidation of the business of Hitech through voluntary liquidation process. Pursuant to the ongoing liquidation process, the liquidator of Hitech has transferred the entire business undertaking to the Company on a going concern basis on and with effect from 04 June 2022.
- 7 On 16 November 2022, the Income Tax department conducted searches at the premises of the Company and some of its subsidiaries. No assets of the Company or its subsidiaries were seized during this process. The Company has been providing from time to time the information and clarifications sought by the Income Tax authorities. Subsequently, including during the current quarter, the Company and some of its subsidiaries have received notices under sections 147 and 148 of the Income Tax Act, 1961, that provide for the reopening of past assessment proceedings. Presently, there is no demand, and accordingly, no adjustments have been made in the financial results.
- 8 On review of the pattern of consumption of the future economic benefits embodied in the assets, it was noted that there has been change in expected pattern of consumption of these benefits. Accordingly, with effect from 01 April 2023, the Group has changed its depreciation/amortization method to Straight Line method from Written down value method for various class of assets to reflect this change. Such a change has been accounted for as a change in an accounting estimate in accordance with Ind AS 8 "Accounting Policies, Change in Accounting Estimates and Errors". Had the Group continued the previous Written Down Value Method for charging depreciation on all class of assets, charge for depreciation/amortisation for the quarter ended 30 June 2023 and for future period would have been higher by Rs. 273.26 lakhs and Rs. 687.57 lakhs respectively and consequentially deferred tax charge on the same for the quarter ended 30 June 2023 and for future period would have been lower by Rs. 68.78 lakhs and Rs. 173.06 lakhs respectively.
- 9 The results of the Group are available for investors at www.metropolisindia.com, www.nseindia.com and www.bseindia.com

For Metropolis Healthcare Limited

Ameera Shah
Managing Director
DIN: 00208095
Place: Mumbai
Date: 02 August 2023



**Details pursuant to Regulation 30 of SEBI Listing Regulations read with SEBI Circular
No. CIR/CFD/CMD/4/2015 dated September 09, 2015:**

Sr No.	Particulars	Details
1.	Name of Director	Mr. Subramanian Ranganathan (DIN: 00125493)
2.	Reason for change viz. appointment, resignation, removal, death or otherwise	Appointment
3.	Date of appointment/cessation and term of appointment (as applicable)	With effect from August 21, 2023 for a term of 5 year, subject to approval of shareholders
4.	Brief Profile (in case of appointment)	<p>Mr. Subramanian Ranganathan is a highly accomplished professional holding a Commerce degree with a specialization in Accounting and an L.L.B. in General Law. He is a member of prestigious institutes like the Institute of Chartered Accountants of India, the Institute of Company Secretaries of India, and the Institute of Cost & Works Accountants of India.</p> <p>He has more than 4 decades of experience in Finance & Management. His recent job experience includes being Managing Director of ECL Finance Limited & President & Group CFO of Edelweiss Financial Services Limited</p>
5.	Disclosure of Relationships between directors (in case of appointment of a director)	Not related with any Director

BLOOD TESTS • DIAGNOSTICS • WELLNESS

METROPOLIS
The Pathology Specialist

Metropolis Healthcare Limited

Registered & Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030.
CIN: L73100MH2000PLC192798 Tel No.: 8422 801 801 Email: support@metropolisindia.com

Website: www.metropolisindia.com

Global Reference Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070.

Details of Re-Constitution of Board Committees:• **Audit Committee (with effect from September 07, 2023):**

Sr No.	Name of the Members	
	Old Composition	New Composition
1	Mr. Milind Sarwate – Chairman	Mr. Subramanian Ranganathan -Chairman
2	Mr. Vivek Gambhir – Member	Mr. Vivek Gambhir – Member
3	Mr. Sanjay Bhatnagar – Member	Mr. Sanjay Bhatnagar – Member
4	Ms. Anita Ramachandran – Member	Ms. Anita Ramachandran – Member

• **Risk Management Committee (with effect from September 07, 2023):**

Sr No.	Name of the Members	
	Old Composition	New Composition
1	Ms. Ameera Shah – Chairperson	Ms. Ameera Shah – Chairperson
2	Mr. Milind Sarwate- Member	Mr. Subramanian Ranganathan - Member
3	Mr. Surendran Chemmenkotil – Member	Mr. Surendran Chemmenkotil – Member

• **Corporate Social Responsibility Committee (with effect from September 07, 2023):**

Sr No.	Name of the Members	
	Old Composition	New Composition
1	Ms. Anita Ramachandran – Chairperson	Ms. Anita Ramachandran – Chairperson
2	Ms. Ameera Shah – Member	Ms. Ameera Shah – Member
3	Mr. Milind Sarwate - Member	Mr. Subramanian Ranganathan - Member

BLOOD TESTS • DIAGNOSTICS • WELLNESS


METROPOLIS
The Pathology Specialist

Metropolis Healthcare Limited

Registered & Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030.

CIN: L73100MH2000PLC192798 Tel No.: 8422 801 801 Email: support@metropolisindia.comWebsite: www.metropolisindia.com

Global Reference Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070.

Brief Profile of Mr. Mohan Menon:

Sr No.	Particulars	Details
1.	Name of Senior Management Personnel	Mr. Mohan Menon
2.	Reason for change viz. appointment, resignation, removal, death or otherwise	Appointment
3.	Date of appointment/cessation and term of appointment (as applicable)	August 02, 2023.
4.	Brief Profile (in case of appointment)	<p>Mr. Mohan is an MBA (Marketing and Operations) from Narsee Monjee Institute of Management Studies and holds an Engineering Degree with specialization in Computer Science from Dr. Babasaheb Ambedkar Marathwada University.</p> <p>Mr. Mohan comes on Board with 18 years of diverse experience across various markets and has been associated in the past with organizations like Max Healthcare, Micromax Mobiles, American Express and Samsung India.</p>
5.	Disclosure of Relationships between directors (in case of appointment of a director)	Not applicable

BLOOD TESTS • DIAGNOSTICS • WELLNESS**Metropolis Healthcare Limited**

Registered & Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030.

CIN: L73100MH2000PLC192798 Tel No.: 8422 801 801 Email: support@metropolisindia.com

Website: www.metropolisindia.com

Global Reference Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070.